Aclaris Therapeutics (NASDAQ:ACRS) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Aclaris Therapeutics (NASDAQ:ACRS) released its quarterly earnings data on Wednesday. The biotechnology company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.03), Zacks reports. The business had revenue of $4.35 million during the quarter, compared to analyst estimates of $8.31 million. Aclaris Therapeutics had a negative net margin of 183.28% and a negative return on equity of 53.18%.

Aclaris Therapeutics Stock Up 8.4 %

NASDAQ ACRS traded up $0.19 on Thursday, reaching $2.45. The stock had a trading volume of 1,005,888 shares, compared to its average volume of 998,016. The stock has a fifty day moving average price of $1.32 and a two-hundred day moving average price of $1.24. Aclaris Therapeutics has a 12-month low of $0.59 and a 12-month high of $5.61. The firm has a market capitalization of $174.80 million, a price-to-earnings ratio of -2.99 and a beta of 0.10.

Analysts Set New Price Targets

Several equities research analysts have issued reports on ACRS shares. HC Wainwright reissued a “neutral” rating on shares of Aclaris Therapeutics in a research note on Tuesday, September 17th. StockNews.com lowered shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday. One equities research analyst has rated the stock with a sell rating and six have issued a hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $9.00.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.